It Seems Enanta Pharmaceuticals Inc (ENTA) Will Go Up. Formed A Few Months Bullish Wedge Up Chart Pattern

November 15, 2017 - By Henry Gaston

Investors sentiment decreased to 0.85 in 2017 Q2. Its down 0.09, from 0.94 in 2017Q1. It dived, as 12 investors sold Enanta Pharmaceuticals Inc shares while 42 reduced holdings. 13 funds opened positions while 33 raised stakes. 11.77 million shares or 2.06% more from 11.53 million shares in 2017Q1 were reported.
Great West Life Assurance Can has invested 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Pinebridge Invests L P has 1,830 shares for 0% of their portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0% or 549 shares. Meeder Asset Mgmt has 0% invested in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 155 shares. United Services Automobile Association accumulated 47,800 shares or 0.01% of the stock. State Common Retirement Fund holds 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 37,078 shares. Ny State Teachers Retirement System has invested 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Granahan Mngmt Inc Ma holds 0.5% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 151,695 shares. Gsa Capital Ptnrs Limited Liability Partnership reported 8,100 shares or 0.02% of all its holdings. Louisiana State Employees Retirement holds 0.01% or 5,700 shares in its portfolio. Envestnet Asset Mngmt holds 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 2 shares. Citigroup holds 30,515 shares. Capstone Asset Management Communication has invested 0.01% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Proshare Ltd Llc accumulated 11,375 shares. Baldwin Brothers Ma invested 0.01% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA).

The stock of Enanta Pharmaceuticals Inc (ENTA) formed an up wedge with $49.46 target or 5.00 % above today’s $47.10 share price. The 8 months wedge indicates low risk for the $899.25 million company. If the $49.46 price target is reached, the company will be worth $44.96 million more.
Rising wedges, especially for downward breakouts are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 8% and 24%. The average rise is 28% and the decline is 14%. Wedges has high throwback and pullback rate: 73%, 63% and the percent of wedges meeting target is not more than 50%.

About 23,487 shares traded. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has risen 40.91% since November 15, 2016 and is uptrending. It has outperformed by 24.21% the S&P500.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Ratings Coverage

Among 5 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Enanta Pharmaceuticals Inc had 17 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Market Outperform” rating on Tuesday, July 11 by JMP Securities. As per Saturday, August 8, the company rating was downgraded by TheStreet. The rating was downgraded by Zacks to “Buy” on Friday, August 7. The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has “Hold” rating given on Friday, September 15 by Robert W. Baird. The rating was downgraded by Barclays Capital to “Underweight” on Friday, October 23. The firm earned “Mkt Outperform” rating on Friday, October 23 by JMP Securities. The rating was maintained by RBC Capital Markets with “Buy” on Friday, October 20. JMP Securities downgraded the shares of ENTA in report on Thursday, April 28 to “Market Perform” rating. JP Morgan maintained the shares of ENTA in report on Tuesday, August 9 with “Overweight” rating. The company was maintained on Tuesday, August 8 by Robert W. Baird.

More notable recent Enanta Pharmaceuticals Inc (NASDAQ:ENTA) news were published by: Businesswire.com which released: “Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 pm ET to …” on November 13, 2017, also Businesswire.com with their article: “Enanta Pharmaceuticals Announces New Data Presentations on EDP-305, an FXR …” published on September 27, 2017, Businesswire.com published: “Enanta Pharmaceuticals Ranked as One of North America’s Fastest Growing …” on November 10, 2017. More interesting news about Enanta Pharmaceuticals Inc (NASDAQ:ENTA) were released by: Seekingalpha.com and their article: “Enanta Pharmaceuticals: Updates To Thesis” published on August 06, 2017 as well as Seekingalpha.com‘s news article titled: “Enanta Pharmaceuticals’ (ENTA) CEO Jay Luly on Q2 2017 Results – Earnings Call …” with publication date: May 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.